Brokerages Expect Aethlon Medical, Inc. (NASDAQ:AEMD) Will Announce Quarterly Sales of $80,000.00

Wall Street brokerages expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report sales of $80,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Aethlon Medical’s earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $100,000.00. Aethlon Medical posted sales of $70,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 14.3%. The firm is expected to issue its next earnings results after the market closes on Monday, July 1st.

According to Zacks, analysts expect that Aethlon Medical will report full-year sales of $200,000.00 for the current fiscal year. For the next year, analysts forecast that the business will post sales of $730,000.00, with estimates ranging from $200,000.00 to $1.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Aethlon Medical.

A hedge fund recently bought a new stake in Aethlon Medical stock. Bank of New York Mellon Corp acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 30,363 shares of the medical equipment provider’s stock, valued at approximately $50,000. Bank of New York Mellon Corp owned approximately 0.17% of Aethlon Medical as of its most recent filing with the SEC. 5.33% of the stock is owned by institutional investors.

NASDAQ:AEMD opened at $0.37 on Friday. The firm has a market cap of $6.63 million, a PE ratio of -0.79 and a beta of 1.32. Aethlon Medical has a one year low of $0.30 and a one year high of $1.74. The firm’s fifty day moving average is $0.38.

About Aethlon Medical

Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.

Further Reading: What is a Swap?

Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.